24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
AHA News: For Kids, a Pandemic of Stress Could Have Long-Term Consequences6 Expert Tips for Defusing Kids' Quarantine MeltdownsFor Many Kids, Picky Eating Isn't Just a Phase, Study FindsSure-Fire Solutions for Managing Lockdown Temper TantrumsKeeping Kids Slim, Fit During Lockdown Isn't Easy: Here Are Some TipsCOVID-19 Antibodies May Tame Inflammatory Condition in Kids: StudyCould Certain Chemicals Trigger Celiac Disease?Italian Doctors Detail Cases of Inflammatory Condition in Kids With COVID-19AHA News: Is Your Child's Blood Pressure Something to Worry About?Zika Virus Tied to Profound Developmental DelaysCOVID-19 Still Rare in Kids, But Far From Harmless: StudyKids' ER Visits for Mental Health Problems Soared Over 10 YearsTo Prevent Injuries, Give Your Kids a Pass on Cutting the GrassFewer Kids in Cancer Trials, Which Might Not Be a Bad ThingLoving Family May Lower Future Depression Risk in KidsBest Ways to Help Kids Through the PandemicIn Rare Cases, COVID-19 May Be Causing Severe Heart Condition in KidsReplace That Old Carpet to Shield Your Kids From ToxinsCoronavirus Crisis Has Fewer Kids Getting Needed VaccinesAHA News: Traumatic Childhood Increases Lifelong Risk for Heart Disease, Early DeathFDA Bans Products That Help Kids Hide Vape Use From ParentsCalm Parenting Will Help Children Through Coronavirus PandemicStudy Confirms Safety, Effectiveness of Children's VaccinesUp to 50,000 U.S. Kids May Be Hospitalized With COVID-19 by Year's EndAre Immune-Compromised Kids at Greater Risk From COVID-19?All That Social Media Hasn't Hurt Kids' Social Skills, Study FindsKids of Mentally Ill Parents Have Higher Injury OddsSchool Closures Could Be Adding to Kids' WaistlinesU.S. Study Finds COVID-19 Seldom Severe in KidsWhy Your Kids' Playground Is Unsafe During COVID-19 PandemicSchool Closures Will Force Many U.S. Health Care Workers to Stay HomeGoing Easy on Yourself Is Key to Parenting Through the PandemicParents, Arm Your Kids Against COVID-19 With Good Hand-Washing HabitsToo Little Sleep Takes Toll on Kids' Mental Health: StudyU.S. Kids, Teens Eating Better But Nutrition Gaps PersistHow to Keep Housebound Kids Busy During a PandemicCalming Your Child's Coronavirus FearsAnother Study Finds COVID-19 Typically Mild for KidsSoap vs. Coronavirus: Best Hand-Washing Tips for You and Your KidsKids Get Mild COVID-19 Symptoms, But Chance of Transmission High: StudyWhen Chronic Pain Leads to Depression in KidsPost-Game Snacks May Undo Calorie-Burning Benefit of Kids' SportsPick Summer Camps Carefully When Your Kid Has Allergies, AsthmaKids Raised by Grandparents More Likely to Pile on Pounds: StudyKeep Your Kids Safe, Warm in Wintertime FunHow to Dispel Your Child's Fears About the New CoronavirusDiabetes Among U.S. Young, Especially Asians, Continues to ClimbMom-to-Be's Cosmetics Chemicals Could Lead to Heavier BabyMeds May Not Prevent Migraines in KidsAHA News: For Kids With Heart Defects, the Hospital Near Mom May Matter
Questions and AnswersLinks
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Child Development & Parenting: Infants (0-2)
Child Development & Parenting: Early (3-7)

First Drug Approved for Treatment of Peanut Allergy in Children


HealthDay News
Updated: Feb 3rd 2020

new article illustration

MONDAY, Feb. 3, 2020 (HealthDay News) -- The U.S. Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to alleviate allergic reactions to accidental peanut exposure, the agency announced late Friday.

Palforzia, a powder manufactured from peanuts, is indicated for initiation in individuals aged 4 to 17 years old with a confirmed peanut allergy. Treatment may be continued in individuals aged 4 years and older. "When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy," Peter Marks, M.D., Ph.D., director of the FDA Center for Biologics Evaluation and Research, said in an agency news release.

The FDA notes that Palforzia cannot be used for emergency treatment of allergic reactions. Treatment involves three phases, including initial dose escalation, given on a single day; up-dosing, which involves 11 increasing dose levels over several months; and maintenance. The initial dose escalation and the first dose of each up-dosing level are administered under the supervision of a health care professional. Once patients have completed all up-dosing levels, they can begin the maintenance phase. Palforzia is packaged in pull-apart color-coded capsules for the dose escalation and up-dosing levels and is packaged in a sachet for maintenance treatment. The powder from the capsules or sachet is to be mixed with a small amount of food such as applesauce, yogurt, or pudding for the patient to consume.

Approval was based on data from a randomized, double-blind, placebo-controlled study in about 500 peanut-allergic individuals. In an oral challenge after six months of maintenance treatment, 67.2 percent of individuals who received Palforzia tolerated a 600-mg dose of peanut protein with no more than mild allergic symptoms versus 4 percent of those who received placebo. In two double-blind, placebo-controlled studies of about 700 peanut-allergic individuals, the most commonly reported side effects with Palforzia included abdominal pain, vomiting, nausea, tingling in the mouth, itching in the mouth and ears, cough, runny nose, throat irritation and tightness, hives, wheezing, and shortness of breath and anaphylaxis.

Approval was granted to Aimmune Therapeutics.

More Information